Market Chatter: Novo Nordisk Raises $4.7 Billion in Bond Sale to Fund Akero Acquisition-March 2024-www.financetom.com

Market Chatter: Novo Nordisk Raises $4.7 Billion in Bond Sale to Fund Akero Acquisition

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Market Chatter: Novo Nordisk Raises $4.7 Billion in Bond Sale to Fund Akero Acquisition

Nov 13, 2025 10:09 AM

12:51 PM EST, 11/13/2025 (MT Newswires) -- Novo Nordisk ( NVO ) raised 4 billion euros ($4.7 billion) in a bond sale to help finance its planned acquisition of Akero Therapeutics ( AKRO ) , Bloomberg reported Thursday, citing a person familiar with the deal.

Novo Nordisk ( NVO ) and Akero did not immediately reply to requests for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 49.82, Change: -0.44, Percent Change: -0.88

Previous page： Palo Alto Networks Insider Sold Shares Worth $16,082,453, According to a Recent SEC Filing Next page： Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Palo Alto Networks Insider Sold Shares Worth $16,082,453, According to a Recent SEC Filing

Apr 9, 2024

04:41 PM EDT, 04/09/2024 (MT Newswires) -- Lee Klarich, Executive Vice President, Chief Product Officer, on April 05, 2024, sold 60,000 shares in Palo Alto Networks ( PANW ) for $16,082,453. Following the Form 4 filing with the SEC, Klarich has control over a total of 574,075 shares of the company, with 174,075 shares held directly and 400,000 controlled indirectly....

Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing

Apr 9, 2024

04:42 PM EDT, 04/09/2024 (MT Newswires) -- Fady Ibraham Malik, Executive Vice President, Research & Development, on April 09, 2024, sold 32,605 shares in Cytokinetics ( CYTK ) for $2,422,918. Following the Form 4 filing with the SEC, Malik has control over a total of 138,567 shares of the company, with 138,567 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1061983/000112760224012715/xslF345X03/form4.xml Price: 75,...

United Therapeutics Insider Sold Shares Worth $4,727,736, According to a Recent SEC Filing

Apr 9, 2024

04:40 PM EDT, 04/09/2024 (MT Newswires) -- Martine A Rothblatt, Director, Chairperson & CEO, on April 05, 2024, sold 20,060 shares in United Therapeutics ( UTHR ) for $4,727,736. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 130 shares of the company, with 130 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1082554/000141588924010571/xslF345X03/form4-04092024_040402.xml ...

Shell at disadvantage to US-listed rivals, says former CEO

Apr 9, 2024

LAUSANNE, Switzerland, April 9 (Reuters) - Shell's former CEO, Ben van Beurden, said on Tuesday that European oil and gas companies will find it increasingly difficult to compete with U.S.-listed rivals. There are a deeper pool of investors and capital in New York and the attitude is more positive towards oil and gas companies, van Beurden, who stepped down in...